Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer
Stopped early · Phase 2
Conditions studied: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analogue in treating patients who have advanced liver and/or biliary cancer.
Key facts
- Study ID
- NCT00005997
- Run by
- Case Comprehensive Cancer Center
- People needed
- 72
- Starts
- 1999-04-01
- Expected to finish
- 2005-11-01
- Last updated by the study team
- 2010-06-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Comprehensive Cancer Center at University of Alabama at Birmingham — Birmingham, Alabama, United States
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
- Hillman Cancer Center at University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.